Alliance Pharma (LSE:APH) EV-to-EBITDA : 22.96 (As of Apr. 29, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alliance Pharma's enterprise value is £287.2 Mil. Alliance Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £12.5 Mil. Therefore, Alliance Pharma's EV-to-EBITDA for today is 22.96.

The historical rank and industry rank for Alliance Pharma's EV-to-EBITDA or its related term are showing as below:

LSE:APH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.86 Med: 12.73 Max: 23.76
Current: 22.96

During the past 13 years, the highest EV-to-EBITDA of Alliance Pharma was 23.76. The lowest was 7.86. And the median was 12.73.

LSE:APH's EV-to-EBITDA is ranked worse than
72.46% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.22 vs LSE:APH: 22.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Alliance Pharma's stock price is £0.3495. Alliance Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.014. Therefore, Alliance Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Alliance Pharma EV-to-EBITDA Historical Data

The historical data trend for Alliance Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma EV-to-EBITDA Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBITDA

Get a 7-Day Free Trial

12.95

13.97

16.08

21.60

18.89

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial															-	21.60	-	18.89	-

Competitive Comparison of Alliance Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alliance Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's EV-to-EBITDA falls into.

Alliance Pharma EV-to-EBITDA Calculation

Alliance Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	287.184	/	12.508
	=	22.96

Alliance Pharma's current Enterprise Value is £287.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was £12.5 Mil.

Alliance Pharma (LSE:APH) EV-to-EBITDA Explanation

Alliance Pharma's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.3495	/	-0.014
	=	At Loss

Alliance Pharma's share price for today is £0.3495.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alliance Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.014.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Alliance Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).